Nasus Pharma Ltd. · AMEX:NSRX
Nasus Pharma — Investor Presentation (March 2026)
44 slides from Nasus Pharma's investor presentation, March 2026
Slide 1: A New Frontier in Intranasal Drug Delivery
Please migrate color palette to match website A NEW FRONTIER IN INTRANASAL DRUG DELIVERY A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products Ticker NSRX Exchange NYSE American Company Presentation – March 202
Slide 2: Forward Looking Statements; Disclaimer
Forward Looking Statements; Disclaimer This presentation of Nasus Pharma Ltd. (the “Company”, “Nasus” or “Nasus Pharma”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities law. Words such as “expects,” “intends,” “pla
Slide 3: Company Highlights
Company Highlights Nasus is Uniquely Positioned to Transform Care via Intranasal Drug Delivery NS002 was designed to address Proprietary Nasax powder Use of well-known active limitations of injectable technology aims to enhance pharmaceutical ingredients Epinephrine, with a needle-free, intranasal d
Slide 4: Robust Asset Pipeline Setting Up Potential for Long Term Growth
Robust Asset Pipeline Setting Up Potential for Long Term Growth Transforming Care via Intranasal Drug Delivery Drug Candidate Molecule Indication Preclinical Phase 1 Phase 2 Pivotal Trial Next Milestone Pivotal study NS002 Epinephrine Anaphylaxis Phase 2 repeat dose PK study topline results reported
Slide 5: Proprietary Nasax Platform Enables Superior Drug Absorption
Proprietary Nasax Platform Enables Superior Drug Absorption Powder formulation can reach all parts of nasal cavity; The greater intranasal absorption area enables faster delivery and higher maximal drug concentration compared to liquid formulations Liquid formulation Powder formulation Liquid Spray
Slide 6: NS002: Intranasal Epinephrine
NS002: INTRANASAL EPINEPHRINE
Slide 7: Anaphylaxis: A Time-Critical Medical Emergency
Anaphylaxis: A Time-Critical Medical Emergency Anaphylaxis is a severe allergic reaction; fatal in ~1% of cases1 The standard of care for anaphylaxis is Epinephrine – this is typically self-administered via an Epinephrine auto-injector (EAI) or given via intramuscular (IM) injection by a healthcare
Slide 8: NS002 Designed to Address the Limitations of Intramuscular Epinephrine
NS002 Designed to Address the Limitations of Intramuscular Epinephrine The proposed solution: NS002 Autoinjectors1 with a 12-18 month Product candidate aims to offer shelf-life a needle-free solution, longer shelf-life, easily administered Large and bulky to carry2 15cm by trained professionals and
Slide 9: Anaphylaxis: A Growing Opportunity in a Large Market
Anaphylaxis: A Growing Opportunity in a Large Market Estimated prevalence of anaphylaxis ~1-3% among the global population1 ~$2.3B Global Epinephrine market in 20242 ~40M Patients with type 1 allergies in the U.S.3 +6.5% From 2010 to 20233 CAGR Patients experience severe type I ~20M allergic reactio
Slide 10: NS002: Clear Roadmap to NDA
NS002: Clear Roadmap to NDA • Following FDA guidance based on the 505(b)(2) regulatory pathway • Demonstration of comparable PK/PD to EpiPen® only requirement for regulatory approval • Pivotal trial expected to initiate Q4 2026 • Short and cost-effective clinical development NP007: NS002 Initiate NS
Slide 11: Competitive Landscape Indicates Large Opportunity for Needle-Free Epinephrine
The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine Nasus Pharma5 2 3 Orexo Aquestive ARS Pharma1 (Market Cap $54.3M*) (Market Cap (Market Cap (Market Cap $814.5M*) NS002 SEK892M*) $491.6M*) EpiPen®4 PK Parameters Neffy (nasal spray) (nasal powder) OX640
Slide 12: Market Research Shows Onset of Action is Important to Allergists
Market Research* Shows Onset of Action is Important to Allergists Speed of onset overwhelmingly Time to reach maximum epinephrine concentration Time to therapeutic epinephrine threshold is important to physicians prescribing an impacts caregivers’ recommendation of epinephrine highly clinically mean
Slide 13: NS002: NP007 Single and Repeated Dose
NS002: NP007: SINGLE AND REPEATED DOSE TOPLINE ANALYSIS
Slide 14: Study NP007: Designed to Compare Bioavailability, PK, PD and Safety
Study NP007: Designed to Compare Bioavailability, PK, PD and Safety of Single and Repeat Dosing with and without Nasal Allergic Challenge (NAC) Week 7: Week 5: Nasal allergic 2xNS002 4mg 2w washout challenge L+L nostril 2xNS002 4mg Week 1: L+L nostril Week 4: Group 1 Nasal allergic Week 2: Week 3: 2
Slide 15: Study NP007 Strengthens NS002's Potential to be Best in Class
Study NP007 Strengthens NS002’s Potential to be Best in Class 1 Study confirms prior PK and safety findings, further demonstrating attributes of nasal powder technology: Rapid and high absorption of Epinephrine. NS002 demonstrated faster absorption of epinephrine: 2 • Shorter Tmax and T100 than EpiP
Slide 16: NS002 Demonstrates Faster, Higher and Sustained Epinephrine Absorption
NS002 Demonstrates Faster, Higher and Sustained Epinephrine Absorption in Critical Therapeutic Window Geometric mean plasma epinephrine concentration over time (Baseline adjusted): NP007 Ph2 topline analysis Single dose: Geometric mean, 1h (baseline adjusted, pg/mL) 400 350 Plasma epinephrine (pg/mL
Slide 17: NS002 Single Dose vs. EpiPen: Comparable Cmax, Shorter Tmax and T100
NS002 Single Dose vs. EpiPen® : Comparable Cmax (normal conditions), Shorter Tmax and T100 Cmax (pg/mL) Tmax (min.) T100 (min.) Geometric mean median median 700.0 25 4 p = 0.033 3.42 19.8 3.5 600.0 539.3 20 513.7 3 Tmax, median (min.) T100, median (min.) Cmax (pg/mL) 500.0 15 15 2.5 400.0 379.1 2 1.
Slide 18: More Participants Achieved Epinephrine Threshold with NS002 than EpiPen
More Participants Achieved Epinephrine Threshold with NS002 compared to EpiPen® in the Critical Time Window Single dose: Proportion (%) who reached 100pg/mL p-value NS002 (χ2 test) EpiPen® (NP007) Normal Normal Time (min) NAC NAC conditions conditions 2.5 67.4% 65.3% 27.1% 0.0001 0.0002 5 88.4% 75.5
Slide 19: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Range
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Range Median change from baseline - Systolic blood pressure (Single dose) 15 10 Baseline mm Hg (median): Median change (mm Hg) 5 NAC+Nasus x1 EpiPen Nasus x1 0 0 20 40 60 80 100 120 -5 115.0 115.0 112.0 -10 A. NAC+ Nasus 4mg B. Epi
Slide 20: NS002 Pharmacodynamic Response Tracks EpiPen: Heart Rate
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Range Median change from baseline- Heart rate (Single dose) 10 Baseline BPM (median): HR Median change (BPM) 8 6 4 NAC+Nasus x1 EpiPen Nasus x1 2 0 -2 0 20 40 60 80 100 120 -4 74.0 75.0 71.0 -6 Time (min.) A. NAC+ Nasus 4mg B. EpiP
Slide 21: Repeat Dosing Continues to Demonstrate Faster, Higher Absorption
Repeat Dosing Continues to Demonstrate Faster, Higher and Sustained Absorption in a Dose Proportional Manner Normal conditions (baseline adjusted): NAC conditions (baseline adjusted): Geometric mean+SE, 0.5hr Geometric mean+SE, 0.5hr 1000 1000 900 900 800 800 Plasma epinephrine (pg/mL) Plasma epinep
Slide 22: NS002 Repeat Dosing Maintains Favorable PK Profile
NS002 Repeat Dosing Maintains Favorable PK Profile Observed with Single Dosing Tmax (min.) median Cmax (pg/mL) Geometric mean 25 p = 0.001 1400.0 p = 0.022 1200.0 19.8 19.8 19.8 1053.7 20 1024.5 Tmax, median (min.) 1020.8 1000.0 845.9 883.8 15 15 Cmax (pg/mL) 15 800.0 600.0 10 400.0 200.0 5 0.0 0 D.
Slide 23: NS002 Well Tolerated after Single and Repeat Administration
Study NP007 Demonstrates that NS002 is Well Tolerated after Single and Repeat Administration (50 participants and 421 drug administrations) • No SAEs reported • No CV AEs • Most AEs were local in nature and self resolving, with 95% mild and 5% moderate. • 1 participant discontinued due to eye pain.
Slide 24: NP007: Summary and Conclusions
NP007: Summary and Conclusions NS002 demonstrated potential best-in-class attributes for epinephrine delivery 01 NS002 reached the Epinephrine therapeutic plasma threshold significantly faster than EpiPen® in all conditions More participants achieved therapeutic epinephrine threshold in the first 5
Slide 25: Strong Global IP Position
Strong Global IP Position Patent No./ Grant Date/ Country App. No. Filed Status/Next action Expiration date Publication No. Pub. Date PCT PCT/IL2018/050914 19/08/2018 WO 2019/038756 A1 National Phase entered 19/08/2038 Australia 2018319592 19/08/2018 2018319592 10/10/2024 Granted 19/08/2038 Canada 3
Slide 26: Strong Global IP Position
Strong Global IP Position Patent No./ Grant Date/ Country App. No. Filed Status/Next action Expiration date Publication No. Pub. Date USA 62/989,913 16/03/2020 Term Ended 16/03/2040 USA 17/135,528 28/12/2020 11,400,045 02/08/2022 Granted 28/12/2040 PCT PCT/IL2021/050288 16/03/2021 WO 2021/186437 23/
Slide 27: Nasus is Uniquely Positioned to Transform Care via Intranasal Delivery
Proprietary Nasax powder technology designed to enhance intranasal drug absorption Lead product candidate NS002 is needle-free, convenient, and easily administered; aiming to offer an alternative to Epinephrine autoinjectors and directly addressing the currently unmet need Multiple Phase 2 studies c
Slide 28: Leadership Team
Leadership Team Udi Gilboa, Co-Founder & Executive Chairman Mr. Gilboa is a prominent serial life sciences entrepreneur and the co-founder of multiple medical device and pharmaceutical companies. He co-founded and served as director and CFO of BioBlast Ltd (NASDAQ: ORPN), Alcobra Ltd (NASDAQ: ADHD),
Slide 29: A New Frontier in Intranasal Drug Delivery
Please migrate color palette to match website A NEW FRONTIER IN INTRANASAL DRUG DELIVERY A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exchange NYSE Ame
Slide 30: NS002: NP002 Pilot Study
NS002: NP002: PILOT STUDY
Slide 31: NS002 Single Dose vs. EpiPen: Comparable Cmax, Shorter Tmax and T100
NS002 Single Dose vs. EpiPen® : Comparable Cmax (normal conditions), Shorter Tmax and T100 Cmax (pg/mL) Tmax (min.) T100 (min.) Geometric mean median median 700.0 25 4 3.42 19.8 3.5 600.0 539.3 20 513.7 3 Tmax, median (min.) Tmax, median (min.) Cmax (pg/mL) 500.0 15 15 2.5 400.0 379.1 2 1.69 300.0 1
Slide 32: NP002: NS002 Pilot Study Overview
NP002: NS002 Pilot Study Overview Study goal: Test NS002’s Epinephrine bioavailability following allergenic challenge PK/PD measurements: plasma Epinepherine, Tmax, T100, AUC, SBP, HR 12 healthy adults with allergic rhinitis (9 male, 3 female) Screening: positive to skin allergen test Period 1 Perio
Slide 33: NP002: Faster, Higher and Sustained Absorption in Critical Therapeutic Window
NP002: Faster, Higher and Sustained Absorption in Critical Therapeutic Window Pilot Study Pharmacokinetics (PK) Plasma epinephrine – geometric mean – 60 min. n=12 33
Slide 34: NS002 vs. EpiPen: Shorter Tmax and T100 and Higher Absorption
NS002 vs. EpiPen®: Shorter Tmax and T100 and Higher Absorption Pilot study PK – baseline corrected time medians Area Under Curve Tmax median (min.) n=12 n=12 20.00 16.50 15.00 Tmax (min.) 9.00 8.98 10.00 5.99 5.00 2.50 0.00 EpiPen Nasus 1.6mg Nasus Nasus 3.2mg Nasus 1.6mg+Allergic 3.2mg+Allergic cha
Slide 35: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Limits
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Pilot study pharmacodynamics (PD) Systolic Blood Pressure n=12 125 120 SBP (mm Hg) EpiPen 115 Nasus 1.6mg normal condition 110 Nasus 1.6mg allergenic challenge 105 Nasus 3.2mg normal condition Nasus 3.2mg allergenic challeng
Slide 36: NS002: NP006 Phase 2 Single Dose Study
NS002: NP006: PHASE 2 SINGLE DOSE STUDY
Slide 37: NP006: NS002 Phase 2 Study Designed to Assess Safety and Tolerability
NP006: NS002 Phase 2 Study Designed to Assess Safety and Tolerability of Single Dose Administration 1 week 1 week Arm 1: N=6 B C A Nasus spray 3.6mg Nasus spray 4.0mg On each dosing day: EpiPen® in one nostril in one nostril Screening PK sampling: 12 healthy -1 to 2hr. (13 samples) volunteers, age 1
Slide 38: More Subjects Achieved Epinephrine Threshold with NS002 Compared to EpiPen
More Subjects Achieved Epinephrine Threshold with NS002 Compared to EpiPen® NP006 Phase 2 PK results Plasma Epinephrine Results 12 healthy subjects 6min EpiPen® 55 % Nasus 3.6mg 72 % Nasus 4.0mg 91% Proportion of subjects achieving clinical threshold of 100pg/mL at 6min * None of the studies of NS-0
Slide 39: NS002 Single Dose vs. EpiPen: Higher Cmax, Shorter Tmax and T100
NS002 Single Dose vs. EpiPen©: Higher Cmax, Shorter Tmax and T100 Phase 2 Results - Cmax, Tmax and T100pg/mL Tmax (median, minutes) n=12 T100pg/mL (median, minutes) n=12 Cmax (Geometric mean + SD) n=12 1400 16 10 15 9 9 1200 14 8 12 1000 7 Mean Cmax (pg/mL) Median T100 (min.) Median Tmax (min.) 10 1
Slide 40: NS002 Achieved Higher Absorption vs. EpiPen in the Critical Therapeutic Window
NS002 Achieved Higher Absorption vs. EpiPen® in the Critical Therapeutic Window Mean AUC0-4min +SD n=12 Mean AUC0-10min +SD n=12 70 140 60 120 Mean AUC h*pg/mL Mean AUC h*pg/mL 50 100 40 80 27.44 63.96 30 50.99 60 20 14.17 40 27.38 10 5.85 20 0 0 EpiPen Nasus 3.6mg Nasus 4.0mg Phase 2 EpiPen Nasus 3
Slide 41: NP006: NS002 Pharmacodynamic Response Tracks EpiPen
NP006: NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Heart Rate Heart Rate n=12 Systolic Blood Pressure n=12 140 90 130 85 Systolic BP (mean) Phase 2: 80 HR (mean) 120 PD results 110 75 70 100 65 90 0 20 40 60 80 100 120 0 20 40 60 80 100 120 Time (min.) Time (min.) Res
Slide 42: NP006: Results Summary
NP006: Results Summary NS002 Could Be a Compelling Alternative to Epinephrine Autoinjectors, with Faster, Greater and Well-Tolerated Epinephrine Delivery 01 NS002 reached the Epinephrine therapeutic plasma threshold faster than EpiPen® 02 Maximum Epinephrine absorption (Tmax) achieved significantly
Slide 43: NS001: Intranasal Naloxone
NS001: INTRANASAL NALOXONE 43
Slide 44: Pivotal Study Validated the Superiority of Powder over Liquid
Pivotal Study Validated the Superiority of Powder over Liquid, Demonstrating Nasax Platform Delivers Naloxone Faster Compared to Narcan® In our phase 3 (n=42) intranasal naloxone study (NS-001), our formulation provided faster delivery and higher mean absorption of naloxone compared to Narcan® The r